“While the phase 3 results of GCAptAIN did not replicate the positive outcomes observed in the phase 2 trial, we remain committed to continuing to drive scientific progress and deepening the ...

Novartis NVS announced that a late-stage study of its interleukin-17A inhibitor, Cosentyx (secukinumab), has failed to meet ...

Novartis is falling farther behind AbbVie, which expanded its JAK inhibitor Rinvoq into giant cell arteritis in April.

Cosentyx missed its main goal in a Phase 3 GCA study, but showed lower steroid use. Novartis plans full review of the trial ...

Novartis (NYSE:NVS) (OTCPK:NVSEF) announced Thursday that its FDA-approved anti-inflammatory agent Cosentyx failed to reach ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

Both polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) present with a broad spectrum of clinical manifestations and almost exclusively occur in the population aged over 50 years. After ...

Current Understanding and Management of Giant Cell Arteritis and Polymyalgia Rheumatica Parasar Ghosh; Frances A Borg; Bhaskar Dasgupta Disclosures Expert Rev Clin Immunol. 2010;6 (6):913-928. 0 ...

Neurona Doses First Patient in Phase 1/2 Trial of NRTX-1001 Cell Therapy in Adults with Drug-Resistant, Bilateral Mesial Temporal Lobe Epilepsy (MTLE) Provided by GlobeNewswire Jun 18, 2025, 5:00: ...

Keywords: giant cell arteritis, ultrasound, relapse, follow-up, large vessel vasculitis Citation: Haaversen ACB, Brekke LK, Kermani TA, Molberg Ø and Diamantopoulos AP (2025) Correction: Vascular ...

In April 2025, the US Food and Drug Administration (FDA) approved Rinvoq® (upadacitinib; AbbVie, Inc) for the treatment of adults with giant cell arteritis (GCA). Upadacitinib is a Janus kinase (JAK) ...